Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MIST 
Milestone Pharmaceuticals Inc (MIST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: MIST (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.33
1 Year Target Price $3.33
| 0 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.68% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 99.44M USD | Price to earnings Ratio - | 1Y Target Price 3.33 |
Price to earnings Ratio - | 1Y Target Price 3.33 | ||
Volume (30-day avg) 4 | Beta 0.92 | 52 Weeks Range 0.62 - 2.75 | Updated Date 06/30/2025 |
52 Weeks Range 0.62 - 2.75 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.77 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.29% | Return on Equity (TTM) -307.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 99072547 | Price to Sales(TTM) 77.32 |
Enterprise Value 99072547 | Price to Sales(TTM) 77.32 | ||
Enterprise Value to Revenue 81.44 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 53464300 | Shares Floating 50946026 |
Shares Outstanding 53464300 | Shares Floating 50946026 | ||
Percent Insiders 4.71 | Percent Institutions 22.25 |
Analyst Ratings
Rating 2 | Target Price 3.33 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Milestone Pharmaceuticals Inc
Company Overview
History and Background
Milestone Pharmaceuticals Inc. (formerly known as Microdermics Inc.) was founded in 2003. The company focuses on developing and commercializing innovative pharmaceutical products for cardiovascular diseases. Milestone's lead product candidate is etripamil, a novel calcium channel blocker nasal spray.
Core Business Areas
- Cardiovascular Therapeutics: Focuses on developing and commercializing Etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT).
Leadership and Structure
Milestone Pharmaceuticals Inc. is led by a management team with experience in the pharmaceutical industry. The company has a board of directors that provides oversight and guidance.
Top Products and Market Share
Key Offerings
- Etripamil Nasal Spray: Etripamil is a novel calcium channel blocker nasal spray being developed for the acute treatment of paroxysmal supraventricular tachycardia (PSVT). Milestone Pharmaceuticals has been awaiting FDA approval. The current standard of care includes adenosine and vagal maneuvers. Competitors include companies that manufacture Adenosine, and develop and market antiarrhythmic drugs.
Market Dynamics
Industry Overview
The cardiovascular therapeutics market is large and growing, driven by an aging population and increasing prevalence of cardiovascular diseases. There is a need for new and improved treatments for conditions like PSVT.
Positioning
Milestone Pharmaceuticals aims to position etripamil as a convenient and effective alternative to existing treatments for PSVT, such as intravenous adenosine. The ease of administration as a nasal spray gives it a competitive advantage.
Total Addressable Market (TAM)
The estimated TAM for PSVT treatments is significant, potentially reaching hundreds of millions of dollars annually. Milestone's positioning revolves around capturing a substantial share of this market with its unique nasal spray formulation. Exact figures are difficult to determine without market approval.
Upturn SWOT Analysis
Strengths
- Novel delivery method (nasal spray)
- Potential for rapid onset of action
- Potential to reduce reliance on intravenous treatments
- Addresses a specific unmet need in PSVT treatment
Weaknesses
- Single product focus (Etripamil)
- Regulatory approval risk (FDA)
- Commercialization risk (market penetration)
- Relatively small company size
Opportunities
- Expansion of etripamil into other indications
- Partnerships with larger pharmaceutical companies
- Geographic expansion into new markets
- Acquisition of other cardiovascular assets
Threats
- Competition from existing PSVT treatments
- Failure to obtain regulatory approval
- Adverse clinical trial results
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- HLX
- TAK
- MRK
- PFE
Competitive Landscape
Milestone's key advantage lies in its novel nasal spray formulation. However, it faces competition from established companies with existing PSVT treatments and greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial progress and fundraising activities.
Future Projections: Future growth is heavily dependent on FDA approval of etripamil and successful commercialization. Analyst estimates vary depending on the likelihood of approval and market penetration.
Recent Initiatives: Recent initiatives include completing clinical trials, preparing for regulatory submission, and exploring potential commercialization strategies.
Summary
Milestone Pharmaceuticals is a development-stage company focused on Etripamil, a novel nasal spray for PSVT. Its success hinges on FDA approval and effective commercialization. The company's innovative delivery method could provide a competitive edge. Risks include regulatory hurdles and competition from established players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Company Website, Press Releases, Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Milestone Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2019-05-09 | CEO, President & Director Mr. Joseph G. Oliveto M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 33 | Website https://www.milestonepharma.com |
Full time employees 33 | Website https://www.milestonepharma.com | ||
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.